GlycoMimetics reports cash $90.3M; Phase 3 uproleselan data still after 2022

CRESCENT BIOPHARMA, INC.

Cash and equivalents $90.3M at Dec 31, 2021 vs $137.0M at Dec 31, 2020; revenue fell to $1.2M from $10.2M.
Pivotal Phase 3 uproleselan trial in relapsed/refractory AML completed enrollment (388 patients); top-line data expected after year-end 2022.
NCI Phase 2/3 registration trial (newly diagnosed AML) completed Phase 2 enrollment (267 patients); interim analysis planned.
Apollomics initiated Phase 3 uproleselan trial in Greater China in November 2021 after Breakthrough Therapy designation.
Expanded executive team: hired Lisa DeLuca (VP Regulatory), Bruce Johnson (SVP/Chief Commercial Officer), Deepak Tiwari (VP Technical Operations).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.